A source says Teva is finalizing the sale of some $2 billion of assets to clear its Allergan purchase.
Teva Pharmaceutical Industries Ltd is finalizing as much as $2 billion in asset sale agreements to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan Plc's generic drug portfolio, according to a source familiar with the matter. The divestments would boost efforts by Teva, the Israeli pharmaceutical company, to close the deal with Allergan, which is domiciled in Ireland. Teva said in March that a regulatory review of the deal by the U.S. Federal Trade Commission was taking longer than anticipated, and that it expected the transaction to be completed by June. Teva has found buyers for nearly all of the assets it expects to divest, which could be worth as much as $2 billion in total, the source said on Thursday. They include around 50 drugs already on the market and 25 in development that treat illnesses ranging from cancer to respiratory disease and central nervous system disorders, the source said.
Teva is still on track to close the deal next month, the source added, asking not to be identified because the latest developments are not public. Teva declined to comment, Allergan did not immediately respond to requests for comment. Finalizing a divestiture plan does not guarantee approval from the FTC, which can sometimes surprise companies by making demands for additional asset sales or proclaim that a transaction is anti-competitive. Teva's deal with Allergan has been cleared by European antitrust regulators. In July, Teva agreed to buy the generics portfolio of Allergan, solidfying Teva's position as the world's largest generic manufacturer. For Allergan, the transaction will help focus its business on brand-name drugs and provide a massive war chest for future acquisitions. Allergan had subsequently agreed to a $160 billion takeover by larger player Pfizer Inc, but the deal was derailed last month by the U.S. Treasury which introduced rules that eliminated tax benefits central to the transaction.
Earlier in the week Medical Marketing and Media noted:
Neither Allergan CEO and president Brent Saunders nor EVP and president, branded pharma Bill Meury are all that thrilled that the federal government scuttled its merger with Pfizer. They couch their frustration in words like “disappointed” and “surprised” and in phrases like “it was somewhat of a distraction.” They shrug, as if to ask, “What can you do?” At the same time, mere days after the deal collapsed, Saunders and Meury had nary an air of regret about them. Indeed, as they sit together in a bright, cavernous conference room at Allergan's U.S. headquarters, in Parsippany, New Jersey, they exude confidence, competence, and enthusiasm about the company's current arc. Owing to its product-line depth in seven therapeutic categories and a host of novel treatments on the way — plus the imminent infusion of $40.5 billion when the sale of its generics business to Teva is soon finalized — Allergan is well on its way to reinventing itself as a next-gen commercial powerhouse. And that likely would have been the case even if it had ultimately ended up under Pfizer's roof.